Can Cassava Sciences Product PTI-125 Beat Alzheimer’s Disease?

Cassava Sciences Stock is Rallying

Cassava Sciences (SAVA) stock closed on Friday, December 27, 2019 at $5.21, reaching a 52-week high. Today, December 30, 2019 the stock is jumping higher, trading now at $6.40, UP $1.19 despite the underperforming market today.

The reason for investors’ rush to buy the stock is due to the good news from a Phase 2 trial of Cassava’s Alzheimer Disease product PTI-125. The promising data were presented by the firm’s scientists during a late-breaking oral presentation at the 12th International Conference on Clinical Trials on Alzheimer’s Disease (CTAD), in San Diego, Ca. 

See the firm’s press release posted under our Impacting News column.  

The New Data from PT-125

Leave a Reply